← All research updates

Chemotherapy timed to the days right after brain surgery worked in mice

Original title: Targeting therapeutic nanoparticles to the glioblastoma resection margin by harnessing postoperative blood-brain barrier disruption.

How far along is this research?

This was done in animals, not people. Most findings at this stage never become treatments.

This was only done in mice, not in people.

The short version

In mice, giving a common chemotherapy drug in a short window after tumor surgery helped stop the tumor from coming back.

What was studied. Researchers used mice with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary that had surgery to remove the tumor. They tested tiny fat bubbles called liposomes, given into a vein, that can carry a drug.

What they found. The brain has a natural barrier that keeps most drugs out. Right after surgery (0 hours) and again 48 to 72 hours later, that barrier was leaky at the edge of the surgery site. The liposomes gathered at that edge and barely reached other parts of the brain. When the liposomes carried the chemotherapy drug doxorubicin and were given during those leaky windows, a single dose held back tumor regrowth in two mouse models.

What this means, and what it doesn't

What it could mean: Timing may matter a lot. Drugs and drug carriers already used in people might reach leftover tumor cells better if they are given in the first days after surgery. That idea would still need to be tested in people.

What it doesn't mean: This does not mean there is a new treatment you can ask for. The work was done in mice, not in people. It is early animal research and is a long way from everyday care. It is not proof this helps humans, and it is not a promise of a cure.

Source: PubMed, July 29, 2026 · Read the original

This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.

Report a problem with this summary